Temozolomide – what regimen in what situation?
ABSTRACT Temozolomide (Temodal®) an alkylating oral cytotoxic drug, has significantly improved overall survival of patients suffering from malignant brain
tumours and has brought new initiative into the treatment of these tumours. Whereas Temozolomide (TMZ) is approved for the
treatment of first-line glioblastoma and the relapse of glioblastoma and anaplastic glioma and is compassionately used in
other settings including the first-line therapy of anaplastic glioma and low-grade gliomas and the relapse of low-grade gliomas,
medulloblastomas/PNETs and primary CNS-lymphomas are frequently treated with TMZ in a compassionate setting, especially if
they relapse. The various entities are currently undergoing different regimens. These will be discussed in detail.